-- New Technology to Help Accelerate Identification of Drug Safety Signals

Ingenix, a wholly owned subsidiary of UnitedHealth Group (NYSE:UNH), has been selected by the United States Food and Drug Administration (FDA) to help improve the effectiveness and speed of safety evaluations for pharmaceutical agents. The Ingenix program is built around a team of leading epidemiologists, complex analytic tools, and the largest and most complete longitudinal patient database available today. It will work with the FDA to monitor the safety of new drugs as well as conduct ad hoc safety studies on established pharmaceutical agents.

"We are pleased to provide our extensive data resources and analytic capabilities to help the FDA respond to the urgent need for improved drug safety," said Terri Madison, PhD, MPH, president of i3 Drug Safety which will lead the Ingenix program. "These proactive efforts should enhance the FDA's ability to identify and assess issues and potential risks related to pharmaceutical agents in a more timely fashion than ever before."

About Ingenix

A leading health information company, Ingenix provides products and services to a diverse customer base within the health care community. Organizations rely on its innovative technology to improve the delivery and operations of their business. More information about Ingenix and its products and services can be obtained at www.ingenix.com.

About i3

i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout pharmaceutical product lifecycle. It includes: i3 Research, a therapeutically specialized contract research organization; i3 Drug Safety, which is engaged in pharmacovigilance and epidemiology; i3 Statprobe, a technologically focused provider of comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; i3 Magnifi, which provides health economics and outcomes services; and i3 DLN, a provider of certified medical education. i3 helps companies gain sharper insights that lead to improved patient care. For more information, visit www.i3global.com.